mAbs · 2018 · 18 citations · 34 references
PharmacyBiomolecular EngineeringBiotechnologyAntibody EngineeringMonoclonal AntibodiesProtein EngineeringAntibody DiscoveryManufacturing Of Monoclonal AntibodiesMonoclonal Antibody TechnologyRecombinant Antibody ExpressionRecombinant Antibody ProductionTherapeutic Antibody DevelopmentAntibody-dependent Cell-mediated CytotoxicityAntibody-dependent Cellular CytotoxicityCell Line SelectionHost Cell Line EngineeringMonoclonal Antibody DesignRecombinant Antibody EngineeringStable Cell Line EngineeringTherapeutic Antibody Design
(afucosylated mAbs) show enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) and increased efficacy. Here, we describe the development of a robust platform for the manufacture of afucosylated therapeutic mAbs by engineering a Chinese hamster ovary (CHO) host cell line to co-express a mAb with GDP-6-deoxy-D-lyxo-4-hexulose reductase (RMD), a prokaryotic enzyme that deflects an intermediate in the de novo synthesis of fucose to a dead-end product, resulting in the production of afucosylated mAb (GlymaxX™ Technology, ProBioGen). Expression of the mAb and RMD genes was coordinated by co-transfection of separate mAb and RMD vectors or use of an internal ribosome entry site (IRES) element to link the translation of RMD with either the glutamine synthase selection marker or the mAb light chain. The GS-IRES-RMD vector format was more suitable for the rapid generation of high yielding cell lines, secreting afucosylated mAb with titers exceeding 6.0 g/L. These cell lines maintained production of afucosylated mAb over 60 generations, ensuring their suitability for use in large-scale manufacturing. The afucosylated mAbs purified from these RMD-engineered cell lines showed increased binding in a CD16 cellular assay, demonstrating enhancement of ADCC compared to fucosylated control mAb. Furthermore, the afucosylation in these mAbs could be controlled by simple addition of L-fucose in the culture medium, thereby allowing the use of a single cell line for production of the same mAb in fucosylated and afucosylated formats for multiple therapeutic indications.
34
Toyohide Shinkawa, Kazuyasu Nakamura, Naoko Yamane et al. · Journal of Biological Chemistry · 2003 · 1.4K citations · Full text
Computational prediction of proteotypic peptides for quantitative proteomics
Parag Mallick, Markus Schirle, Sharon S. Chen et al. · Nature Biotechnology · 2006 · 694 citations
Naoko Yamane‐Ohnuki, Satoko Kinoshita, Miho Inoue‐Urakubo et al. · Biotechnology and Bioengineering · 2004 · 574 citations
Pharmacy, Biochemistry, Immunology +16